Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Toxicol ; 93(5): 1365-1384, 2019 05.
Article in English | MEDLINE | ID: mdl-30729277

ABSTRACT

Exposure to the chemical warfare nerve agent VX is extremely toxic, causing severe cholinergic symptoms. If not appropriately treated, death ultimately ensues. Based on our previously described whole-body vapor exposure system, we characterized in detail the clinical outcome, including respiratory dynamics, typical of whole-body exposure to lethal doses of VX vapor in freely moving rats. We further evaluated the efficacy of two different antidotal regimens, one comprising a single and the other repeated administration of antidotes, in countering the toxic effects of the exposure. We show that a 15 min exposure to air VX concentrations of 2.34-2.42 mg/m3 induced a late (15-30 min) onset of obvious cholinergic signs, which exacerbated over time, albeit without convulsions. Marked eye pathology was observed, characterized by pupil constriction to pinpoint, excessive lacrimation with red tears (chromodacryorrhea) and corneal damage. Respiratory distress was also evident, characterized by a three-fourfold increase in Penh values, an estimate of lung resistance, and by lung and diaphragm histological damage. A single administration of TAB (the oxime TMB-4, atropine and the anticholinergic and antiglutamatergic benactyzine) at the onset of clinical signs afforded only limited protection (66% survival), with clinical deterioration including weight loss, chromodacryorrhea, corneal damage, increased airway resistance and late death. In contrast, a combined therapy of TAB at the onset of clinical signs and repeated administration of atropine and toxogonin (ATOX) every 3-5 h, a maximum of five i.m. injections, led to 100% survival and a prompt recovery, accompanied by neither the above-described signs of eye pathology, nor by bronchoconstriction and respiratory distress. The necessity of recurrent treatments for successful elimination of VX vapor toxicity strongly supports continuous penetration of VX following termination of VX vapor exposure, most likely from a VX reservoir formed in the skin due to the exposure. This, combined with the above-described eye and respiratory pathology and absence of convulsions, are unique features of whole-body VX vapor exposure as compared to whole-body vapor exposure to other nerve agents, and should accordingly be considered when devising optimal countermeasures and medical protocols for treatment of VX vapor exposure.


Subject(s)
Antidotes/administration & dosage , Atropine/administration & dosage , Benactyzine/administration & dosage , Chemical Warfare Agents/toxicity , Organothiophosphorus Compounds/toxicity , Trimedoxime/administration & dosage , Animals , Antidotes/pharmacology , Atropine/pharmacology , Benactyzine/pharmacology , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/toxicity , Drug Administration Schedule , Drug Combinations , Environmental Exposure/adverse effects , Eye Diseases/chemically induced , Eye Diseases/prevention & control , Male , Obidoxime Chloride/administration & dosage , Organothiophosphorus Compounds/administration & dosage , Rats , Rats, Sprague-Dawley , Respiratory Tract Diseases/chemically induced , Respiratory Tract Diseases/prevention & control , Trimedoxime/pharmacology
2.
Arch Toxicol ; 92(2): 873-892, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29127449

ABSTRACT

VX, a potent inhibitor of cholinesterase (ChE), is considered as one of the most toxic, persistent and least volatile nerve agents. VX is absorbed in various environmental surfaces and is gradually released long after its initial dispersal. Its toxicity is mainly caused by disrupting central and peripheral cholinergic nervous system activity, leading to potential long-term detrimental effects on health. The primary objective of the present study was to assess the threshold VX dose leading to minimal physiological alterations following prolonged VX exposure. Characterization of such a threshold is crucial for dealing with unresolved operative dilemmas such as when it is safe enough to resettle a population that has been evacuated from a VX-contaminated area. Rats, continuously exposed to various doses of VX (0.225-45 µg/kg/day) for 4 weeks via implanted mini-osmotic pumps, showed a dose-dependent and continuous decrease in ChE activity in whole blood, brain and muscles, ranging between 20 and 100%. Exposure to 13.5 µg/kg/day led to a stable low ChE activity level (~ 20%), accompanied by transient and negligible electrocorticogram spectral power transformations, especially in the theta and alpha brain wave frequencies, and a significant decrease in total brain M2 receptor density. These changes were neither accompanied by observable signs of intoxication nor by changes in motor function, circadian rhythm or TSPO level (a reliable marker of brain damage). Following exposure to lower doses of 2.25 and 0.225 µg/kg/day, the only change measured was a reduction in ChE activity of 60 and 20%, respectively. Based on these results, we delineate ChE inhibition as the physiological measure most susceptible to alterations following prolonged VX exposure, and determine for the first time the threshold sub-acute VX dose for minimal physiological effects (up to 20% reduction in ChE activity) in the rat as 0.225 µg/kg/day.


Subject(s)
Cholinesterase Inhibitors/toxicity , Nerve Agents/toxicity , Organothiophosphorus Compounds/toxicity , Animals , Biomarkers/blood , Body Temperature , Body Weight , Brain/drug effects , Carrier Proteins/metabolism , Chemical Warfare Agents/toxicity , Cholinesterases/blood , Cholinesterases/metabolism , Dose-Response Relationship, Drug , Male , Motor Activity , Muscles/drug effects , Rats , Rats, Sprague-Dawley , Receptor, Muscarinic M2/metabolism , Receptors, GABA-A/metabolism , Toxicity Tests, Chronic
3.
Toxicol Sci ; 146(2): 301-10, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25956921

ABSTRACT

Eye exposure to the extremely toxic organophosphorus sarin results in long-term miosis and visual impairment. As current treatment using atropine or homatropine eye drops may lead to considerable visual side effects, alternative combined treatments of intramuscular (im) oximes (16.8 µmol/kg, im) with atropine (0.5 mg/kg, im) or with the short acting antimuscarinic tropicamide (0.5%; w/v) eye drops were thus evaluated. The combined treatments efficacy following topical exposure to sarin (1 µg) was assessed by measuring pupil width and light reflex using an infra-red based digital photographic system. Results showed that the combined treatment of various oximes with atropine or with topical tropicamide eye drops rapidly reversed the sarin-induced miosis and presented a long-term improvement of 67-98% (oxime+tropicamide) or 84-109% (oxime+atropine) in pupil widening as early as 10-min following treatment. This recovery was shown to persist for at least 8-h following exposure. All combined treatments facilitated the ability of the iris to contract following sarin insult as tested by a light reflex response.Our findings emphasize the high efficacy of im oxime treatment combined with either atropine im or tropicamide eye drops in counteracting sarin-induced ocular insult. Therefore, in a mass casualty scenario the systemic combined treatment may be sufficient to ameliorate sarin-induced ocular insult with no need for additional, topical anticholinergic treatment at least in the initial stage of intoxication. For very mild casualties, who are unlikely to receive im treatment, the combined oxime (im) with topical tropicamide treatment may be sufficient in ameliorating the ocular insult.


Subject(s)
Atropine/pharmacology , Cholinesterase Reactivators/pharmacology , Eye/drug effects , Oximes/pharmacology , Sarin/toxicity , Administration, Ophthalmic , Animals , Atropine/therapeutic use , Drug Synergism , Male , Miosis/drug therapy , Rats , Rats, Long-Evans , Tropicamide/administration & dosage , Tropicamide/pharmacology
4.
Neuroscience ; 143(2): 487-500, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-16997485

ABSTRACT

Activation of protein kinase C (PKC) after robust stimulation is necessary for vesicle pool replenishment in secretory cells. Here we studied the contribution of a prominent downstream PKC target, Munc18-1, to this process in bovine chromaffin cells. In these cells, both activation of endogenous PKC and overexpressing of Munc18-1 promote vesicle pool replenishment after an extensive stimulation. In order to study the physiological relevance of PKC-dependent Munc18-1 phosphorylation, we generated two Munc18-1 phospho-mutants; one that mimics a constitutively PKC-phosphorylated Munc18-1 (i.e. a phosphomimetic mutant; Munc18-1(S313D)) and a second that cannot be PKC-phosphorylated (Munc18-1(3A)). Overexpression of Munc18-1(3A) caused a significant decrease in vesicle pool replenishment following a depleting stimulation, while Munc18-1(S313D) caused a significant increase in vesicle pool replenishment. These findings suggested that the phosphorylation of Munc18-1 by PKC potentiates vesicle pool replenishment. This hypothesis was further strengthened by the finding that overexpression of wild type Munc18-1 in the presence of a PKC inhibitor caused a significant reduction in vesicle pool replenishment, similar to that observed with Munc18-1(3A). Moreover, overexpression of Munc18-1(S313D) in the presence of the PKC inhibitor partly alleviated this attenuation, elucidating Munc18-1's unique contribution to vesicle pool replenishment. Finally, we demonstrate that Munc18-1 promotes vesicle docking in a phosphorylation-independent manner. This is deduced from the findings that both the wild type and the two Munc18-1 phospho-mutants enhanced docking to the same extent in bovine chromaffin cells. We conclude that Munc18-1 facilitates docking in a PKC phosphorylation-independent manner, and that its phosphorylation by PKC potentiates vesicle pool replenishment following a depleting stimulation, at a post-docking stage.


Subject(s)
Chromaffin Cells/physiology , Munc18 Proteins/metabolism , Protein Kinase C/metabolism , Secretory Vesicles/physiology , Adrenal Medulla/cytology , Animals , Aspartic Acid/genetics , Calcium/metabolism , Carbazoles/pharmacology , Cattle , Chromaffin Cells/drug effects , Chromaffin Cells/ultrastructure , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Exocytosis/drug effects , Exocytosis/physiology , Green Fluorescent Proteins/metabolism , Immunohistochemistry/methods , Indoles/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Microscopy, Electron, Transmission/methods , Munc18 Proteins/genetics , Mutagenesis/physiology , Patch-Clamp Techniques/methods , Phorbol 12,13-Dibutyrate , Phosphorylation/drug effects , Protein Kinase C/genetics , Secretory Vesicles/drug effects , Secretory Vesicles/ultrastructure , Serine/genetics , Transfection/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...